

SUPPLEMENTARY MATERIAL

S1. PRISMA Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Lines 6,7
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Lines 34- 51
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Lines 64-66
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Lines 68-70
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Eligibility criteria - Lines 99-108, 111,112 Synthesis and Analysis - Lines 113-115
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Line 93
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Lines 107-112 Supplementary materials page 4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Lines 125-130, 113-115
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Lines 129-130
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Lines 104-108
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	All other variables - Lines 127-134 Funding sources- Lines 85-87 Missing and unclear- Lines 125-126 and 162-165
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Lines 134-145
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Lines 166-168

Section and Topic	Item #	Checklist item	Location where item is reported
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5).	Lines 168-173
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Lines 161-177
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Lines 250-268 Tables 1, 2 and 3
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Lines 163-177
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Lines 171-176
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Lines 174-76
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases)	Lines 136-146
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Lines 150-157
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Lines 188-200 Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Lines 190-197 Figure 1 Supplementary Material 4
Study characteristics	17	Cite each included study and present its characteristics.	Tables 1 and 2 Supplementary Material 3
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Lines 203-226, 236-240 Figures 2
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Tables 1 and 2 Figure 4 Supplementary Materials 5, 6 and 7
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Lines 236-240 Supplementary Material 8
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Figures 4 to 5 Supplementary Materials page 5
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Figure 4 Supplementary

Section and Topic	Item #	Checklist item	Location where item is reported
			material 5
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Supplementary material 5
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Lines 203-248 Figures 2 and 3
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Supplementary Material 8
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Lines 355-365
	23b	Discuss any limitations of the evidence included in the review.	Lines 387-392
	23c	Discuss any limitations of the review processes used.	Lines 362-365
	23d	Discuss implications of the results for practice, policy, and future research.	Lines 451-454
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Lines 75-77
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Lines 75-77
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Lines 75-77
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Lines 473
Competing interests	26	Declare any competing interests of review authors.	Line 458
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Line 459-461 Supplementary materials 1 to 4

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

S2. Concept Map


P	I	C	O
"pregnant women" Mesh	"genotypes" Mesh	any control	"abortion" Mesh
"pregnant women" Emtree	"genotypes" Emtree		"abortion" Emtree
"newborns" Mesh	"strain" Mesh		
"newborns" Emtree	"strain" Emtree		
"fetuses" Mesh	"variant" Mesh		
"fetuses" Emtree	"variant" Emtree		
"children" Mesh	"lineage" Mesh		
"children" Emtree	"lineage" Emtree		
"infants" Mesh			
"infants" Emtree			
<i>"Toxoplasma gondii"</i> Mesh			
<i>"Toxoplasma gondii"</i> Emtree			

S3. Search Strategy Conducted

Table S1. Search strategies for articles to determine the association between *Toxoplasma gondii* infection, its genetic variants, and abortion cases.**Strategy by database**

Strategy by database			Results
EMBASE			6
Population	Intervention	Outcome	
('newborns' OR 'fetuses' OR ('child'/exp OR 'child' OR 'children') OR 'babies' AND ('toxoplasmosis'/exp OR 'T. gondii infection' OR 'T. gondii infections' OR 'Toxoplasma gondii infection' OR 'Toxoplasma gondii infections' OR 'Toxoplasma infection' OR 'Toxoplasma infections' OR 'infection by T. gondii' OR 'infection by Toxoplasma' OR 'infection by Toxoplasma gondii' OR 'infection due to Toxoplasma gondii' OR 'infection with T. gondii' OR 'infection with Toxoplasma' OR 'infection with Toxoplasma gondii' OR 'toxoplasmoses' OR 'toxoplasmosis') [Entree]	('genotype'/exp OR 'genotype') OR ('genetic strain'/exp OR 'genetic strain' OR 'strain, genetic') OR 'strain'/exp OR 'lineage'/exp) [Entree]	('abortion'/exp) [Entree]	
#1 AND 'congenital toxoplasmosis'/dm			
Link:(https://www-embase-com.ez6.periodicos.capes.gov.br/#advancedSearch/resultspage/history.6/page.1/200.items/orderby.date/source.)			
Web of Science			165
(newborns OR fetuses OR children OR babies AND <i>Toxoplasma gondii</i>)(All Fields)	(genotypes OR strain OR variant OR lineage (All Fields)	(abortion)(All Fields)	
Link: https://www.webofscience.com/wos/woscc/summary/3300dc47-8443-48f1-a655-85ea7c5de250-01ada8b19e/relevance/1			
SCIENCE DIRECT			93
(newborns OR fetuses OR babies AND <i>Toxoplasma gondii</i>)	(genotypes OR strain OR variant OR lineage)	(Abortion)	
Link: https://www.sciencedirect.com/search?qs=newborns+OR+fetuses+AND+Toxoplasma+gondii+%28Topic%29+and+genotypes+T.+gondii+OR+strain+T.+gondii+OR+variant+T.+gondii+OR+genotypes+Toxoplasma+gondii+and+abortion&articleTypes=FLA&lastSelectedFacet=subjectAreas&subjectAreas=2400%2C2700			
PUBMED			9
(newborns OR fetuses OR babies AND <i>Toxoplasma gondii</i>)[MeSH Terms]	(genotypes OR strain OR variant OR lineage [MeSH Terms]	(abortion)[MeSH Terms]	
Link: https://pubmed.ncbi.nlm.nih.gov/?term=%28newborns+OR+fetuses+AND+Toxoplasma+gondii+%28Topic%29+and+genotypes+T.+gondii+OR+strain+T.+gondii+OR+variant+T.+gondii+OR+genotypes+Toxoplasma+gondii+and+abortion%29%5BMeSH+Terms%5D&filter=datesearch.y_10&filter=hum_ani.humans&filter=age.allchild&filter=other.excludepreprints&ac=no			

S4. Pooled sensitivity analysis



S5. Sensitivity analysis plot by subgroup

